Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.
Artificial intelligence (AI) drug developer Insilico Medicine says it is planning late-stage trials for its lead clinical candidate rentosertib following publication today of positive mid-stage safety ...
Even a disease as deadly as idiopathic pulmonary fibrosis (IPF) can start out as just a cough. But as the condition progresses, a person might experience up to 500 respiratory spasms per day.
When researchers combined results from two similar studies, the benefits were consistent: better lung function, fewer disease flare-ups, and improved quality of life, United said. ・Tyvaso is already ...
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results